CRISPR Therapeutics AG (CRSP.OQ)
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|49||2017||Chairman of the Board of Directors, President, Founder|
|38||2017||Chief Executive Officer|
|49||2016||Senior Vice President - Strategic Development and Operations|
|Senior Vice President of Human Resources|
|53||2015||Chief Scientific Officer|
- BRIEF-Crispr Therapeutics Qtrly collaboration Revenue $32.3 Mln
- BRIEF-Crispr Therapeutics Says Public Offering Of 5 Mln Common Shares Priced At $22.75/Share
- BRIEF-Crispr Therapeutics Commences Public Offering Of $100 Mln Common Shares
- BRIEF-Vertex, CRISPR Therapeutics To Co-Develop CTX001 As CRISPR/Cas9 Gene Edited Treatment
- BRIEF-CRISPR Therapeutics appoints Michael Tomsicek as CFO